Polyrizon Ltd.(PLRZ)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

PLRZ Polyrizon Ltd.

休市中 05-22 16:00:00 EDT

15.26

+2.61

+20.59%

盘后15.26

+0.000.00%

19:40 EDT

最高15.58	最低12.67	成交量4.70万
今开12.67	昨收12.65	日振幅23.00%
总市值3,010万	流通市值2,333万	总股本197.28万
成交额67.12万	换手率3.07%	流通股本152.96万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"PLRZ","market":"US","secType":"STK","nameCN":"Polyrizon Ltd.","latestPrice":15.255,"timestamp":1779480000000,"preClose":12.65,"halted":0,"volume":47034,"hourTrading":{"tag":"盘后","latestPrice":15.255,"preClose":15.255,"latestTime":"19:40 EDT","volume":75,"amount":1136.575,"timestamp":1779493204317,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.20592885375494074,"floatShares":1529600,"shares":1972800,"eps":-0.71144193,"marketStatus":"休市中","change":2.605,"latestTime":"05-22 16:00:00 EDT","open":12.67,"high":15.58,"low":12.67,"amount":671232,"amplitude":0.23004,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.71144193,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1779782400000},"marketStatusCode":7,"adr":0,"listingDate":1730174400000,"exchange":"NASDAQ","adjPreClose":12.65,"postHourTrading":{"tag":"盘后","latestPrice":15.255,"preClose":15.255,"latestTime":"19:40 EDT","volume":75,"amount":1136.575,"timestamp":1779493204317,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.7678129968070475},"requestUrl":"/m/hq/s/PLRZ","defaultTab":"news","newsList":[{"id":"1162623204","title":"Polyrizon Ltd. 签署协议进行普通股及预融资认股权证的注册直接发行","url":"https://stock-news.laohu8.com/highlight/detail?id=1162623204","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162623204?lang=zh_cn&edition=full","pubTime":"2026-04-07 20:02","pubTimestamp":1775563325,"startTime":"0","endTime":"0","summary":"生物技术公司Polyrizon Ltd. (PLRZ) 近日宣布，该公司已达成最终协议，将通过注册直接发行的方式，向机构投资者发售其普通股及预融资认股权证。\n此次发行旨在为公司的重要研发项目及一般营运资金需求筹集资金。根据市场惯例，此次发行的完成仍需满足特定的交割条件。\n通过这种融资方式，Polyrizon Ltd. 期望能加速其在研管线的进展，并进一步巩固其财务状况。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PLRZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198342122","title":"Polyrizon计划收购先进eVTOL无人机开发商Colugo至多20%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=1198342122","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198342122?lang=zh_cn&edition=full","pubTime":"2026-03-24 20:48","pubTimestamp":1774356518,"startTime":"0","endTime":"0","summary":"Polyrizon Ltd. 已宣布一项战略投资计划，拟收购Colugo公司的部分股权。Colugo是一家专注于研发先进电动垂直起降（eVTOL）无人机的企业，其产品主要应用于国防及城市空中交通领域。根据计划，Polyrizon此次收购的股权比例最高可达20%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177669566","title":"Polyrizon携手全球领先临床前CRO，加速推进临床开发项目","url":"https://stock-news.laohu8.com/highlight/detail?id=1177669566","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177669566?lang=zh_cn&edition=full","pubTime":"2026-03-17 20:27","pubTimestamp":1773750433,"startTime":"0","endTime":"0","summary":"Polyrizon Ltd. (PLRZ) 已与一家全球顶尖的临床前合同研究组织（CRO）正式签署合作协议，此举是其整体临床开发计划中的关键一步。\n该合作旨在利用该CRO在临床前研究领域的专业能力和全球资源，以推进Polyrizon研发管线的进展。协议的签署标志着公司向临床阶段迈出了实质性的一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PLRZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618807421","title":"Polyrizon Ltd.盘中异动 大幅下挫5.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618807421","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618807421?lang=zh_cn&edition=full","pubTime":"2026-03-12 03:40","pubTimestamp":1773258044,"startTime":"0","endTime":"0","summary":"北京时间2026年03月12日03时40分，Polyrizon Ltd.股票出现波动，股价快速下挫5.17%。截至发稿，该股报12.29美元/股，成交量7752股，换手率0.74%，振幅5.48%。Polyrizon Ltd.股票所在的生物技术行业中，整体跌幅为1.05%。Polyrizon Ltd.公司简介：Polyrizon Ltd是一家处于临床开发阶段的生物技术公司，专门开发鼻用凝胶，以提供抵御各种病毒的预防性治疗，包括某些 COVID-19 变种，这些变种也被认为比病毒的原始毒株引起更多的感染并传播得更快，流感、过敏原和其他毒素。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312034044a6b8ccb7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312034044a6b8ccb7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PLRZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146277893","title":"Polyrizon宣布与Eurofins CDMO Amatsiaquitaine S.a.s合作生产cGMP临床实验材料，用于计划中的美国临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1146277893","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146277893?lang=zh_cn&edition=full","pubTime":"2026-03-10 19:55","pubTimestamp":1773143714,"startTime":"0","endTime":"0","summary":"Polyrizon Ltd. 已正式宣布，其将与Eurofins CDMO Amatsiaquitaine S.a.s合作，启动符合药品生产质量管理规范（GMP）的临床实验材料（CTM）生产工作。此项生产旨在为该公司计划在美国开展的临床研究提供所需材料。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PLRZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121429365","title":"Polyrizon宣布其纳洛酮制剂研究取得积极成果，鼻腔沉积特性优于市售参照产品","url":"https://stock-news.laohu8.com/highlight/detail?id=1121429365","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121429365?lang=zh_cn&edition=full","pubTime":"2026-02-26 21:14","pubTimestamp":1772111644,"startTime":"0","endTime":"0","summary":"生物制药公司Polyrizon Ltd.近日公布了一项关于其自主研发的纳洛酮鼻喷雾制剂的实验研究结果。研究数据显示，该公司的创新配方在关键的鼻腔沉积性能方面表现出显著优势，其沉积效果明显优于目前市面上的主流参照产品。\n这一积极成果标志着Polyrizon在药物递送技术领域取得了重要进展，为其纳洛酮产品的后续开发奠定了坚实基础。纳洛酮作为一种用于逆转阿片类药物过量的重要抢救药物，其鼻腔给药形式的有效性至关重要。此次研究的成功，预示着该配方有望为紧急用药场景提供更高效、更可靠的解决方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611018503","title":"Polyrizon Ltd.盘中异动 临近午盘股价大涨5.06%报13.50美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2611018503","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611018503?lang=zh_cn&edition=full","pubTime":"2026-02-13 00:41","pubTimestamp":1770914502,"startTime":"0","endTime":"0","summary":"北京时间2026年02月13日00时41分，Polyrizon Ltd.股票出现异动，股价急速拉升5.06%。截至发稿，该股报13.50美元/股，成交量2.2526万股，换手率2.16%，振幅5.60%。Polyrizon Ltd.股票所在的生物技术行业中，整体跌幅为0.14%。Polyrizon Ltd.公司简介：Polyrizon Ltd是一家处于临床开发阶段的生物技术公司，专门开发鼻用凝胶，以提供抵御各种病毒的预防性治疗，包括某些 COVID-19 变种，这些变种也被认为比病毒的原始毒株引起更多的感染并传播得更快，流感、过敏原和其他毒素。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260213004142a49d39af&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260213004142a49d39af&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PLRZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178859253","title":"Polyrizon Ltd.：签署谅解备忘录后30天内有望达成最终协议，尚待尽职调查","url":"https://stock-news.laohu8.com/highlight/detail?id=1178859253","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178859253?lang=zh_cn&edition=full","pubTime":"2026-02-10 19:59","pubTimestamp":1770724751,"startTime":"0","endTime":"0","summary":"Polyrizon Ltd. 宣布，在签署谅解备忘录后，预计将在30天内完成最终协议的签订。此项进程的推进，将以顺利完成尽职调查为前提条件。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610610896","title":"Polyrizon Ltd.盘中异动 早盘股价大跌6.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610610896","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610610896?lang=zh_cn&edition=full","pubTime":"2026-02-09 22:52","pubTimestamp":1770648721,"startTime":"0","endTime":"0","summary":"北京时间2026年02月09日22时52分，Polyrizon Ltd.股票出现波动，股价大幅跳水6.34%。截至发稿，该股报12.03美元/股，成交量4461股，换手率0.43%，振幅5.50%。Polyrizon Ltd.股票所在的生物技术行业中，整体跌幅为0.07%。Polyrizon Ltd.公司简介：Polyrizon Ltd是一家处于临床开发阶段的生物技术公司，专门开发鼻用凝胶，以提供抵御各种病毒的预防性治疗，包括某些 COVID-19 变种，这些变种也被认为比病毒的原始毒株引起更多的感染并传播得更快，流感、过敏原和其他毒素。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020922520197a58300&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020922520197a58300&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PLRZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183826025","title":"Polyrizon与合作伙伴达成协议，共同开发专有非致幻性神经可塑性药物鼻腔制剂","url":"https://stock-news.laohu8.com/highlight/detail?id=1183826025","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183826025?lang=zh_cn&edition=full","pubTime":"2026-02-06 20:56","pubTimestamp":1770382574,"startTime":"0","endTime":"0","summary":"生物医药公司Polyrizon Ltd.近日宣布，已签署一项重要合作协议，旨在推进其专有的非致幻性神经可塑性药物（Neuroplastogen）鼻腔制剂的研发进程。该合作标志着公司在创新神经科学疗法领域迈出了关键一步。\n此次开发的鼻腔制剂采用了独特的技术路径，旨在通过鼻内给药方式靶向神经系统，促进神经可塑性，同时避免了传统精神活性物质常见的致幻副作用。这一特性使其在治疗抑郁症、创伤后应激障碍等神经系统相关疾病方面具有广阔的临床应用潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ","CMND","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173106061","title":"Clearmind Medicine签署开发协议，推进其专有无致幻神经塑性药物Meai的鼻内制剂研发","url":"https://stock-news.laohu8.com/highlight/detail?id=1173106061","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173106061?lang=zh_cn&edition=full","pubTime":"2026-02-06 20:56","pubTimestamp":1770382573,"startTime":"0","endTime":"0","summary":"Clearmind Medicine Inc. 近日与Polyrizon Ltd. 达成一项开发合作协议，旨在加速其专有无致幻神经塑性化合物Meai的鼻内制剂研发进程。该合作将结合Clearmind在神经科学领域的专长与Polyrizon在药物递送技术方面的优势，共同推进新型治疗方案的开发。此次合作标志着公司在非致幻性神经可塑性药物研发领域迈出重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMND","BK4007","PLRZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608582476","title":"Polyrizon Ltd.股价飙升12.25% 市值涨164.86万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608582476","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608582476?lang=zh_cn&edition=full","pubTime":"2026-02-02 22:35","pubTimestamp":1770042902,"startTime":"0","endTime":"0","summary":"北京时间2026年02月02日22时35分，Polyrizon Ltd.股票出现波动，股价急速上涨12.25%。截至发稿，该股报12.92美元/股，成交量1.5876万股，换手率1.52%，振幅4.17%。Polyrizon Ltd.股票所在的生物技术行业中，整体跌幅为0.05%。其相关个股中，60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Polyrizon Ltd.、Verrica制药涨幅较大，60 Degrees Pharmaceuticals, Inc.、Vivosim Labs, Inc.、Vyome Holdings, Inc.较为活跃，换手率分别为248.27%、17.03%、14.96%，振幅较大的相关个股有Bioatla, Inc.、Context Therapeutics Inc.、天演药业，振幅分别为27.73%、18.39%、15.27%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260202223502a6cab6b9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260202223502a6cab6b9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PLRZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117300089","title":"Polyrizon启动Nasarix™过敏阻断剂可用性研究项目，推进监管审批进程","url":"https://stock-news.laohu8.com/highlight/detail?id=1117300089","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117300089?lang=zh_cn&edition=full","pubTime":"2026-01-22 22:27","pubTimestamp":1769092073,"startTime":"0","endTime":"0","summary":"Polyrizon有限公司在推进其主打产品Nasarix™过敏阻断剂的监管审批道路上迈出了关键一步，正式启动了该产品的可用性研究项目。这一举措旨在评估产品的实际使用体验与性能，为后续向监管机构提交申请收集必要的数据支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108909694","title":"Polyrizon Ltd. 董事会批准进行选择性投资，预计将产生近期收益","url":"https://stock-news.laohu8.com/highlight/detail?id=1108909694","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108909694?lang=zh_cn&edition=full","pubTime":"2026-01-13 21:46","pubTimestamp":1768311997,"startTime":"0","endTime":"0","summary":"Polyrizon Ltd. 宣布，其董事会已正式批准一项战略计划，将着手进行一系列选择性投资。公司方面表示，这些经过精心筛选的投资项目，预计将在短期内为公司带来可观的收入增长。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176001861","title":"Polyrizon Ltd. 初期战略聚焦高潜力领域运营公司，涵盖国防、航空及人工智能","url":"https://stock-news.laohu8.com/highlight/detail?id=1176001861","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176001861?lang=zh_cn&edition=full","pubTime":"2026-01-13 21:44","pubTimestamp":1768311852,"startTime":"0","endTime":"0","summary":"Polyrizon Ltd. 正将其初步发展重心，精准锁定于多个高增长潜力行业的运营公司。其战略布局尤其关注国防、航空以及人工智能等前沿领域。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109995262","title":"Polyrizon 向 FDA 提交 PL-16 病毒阻断剂的前期指定请求，旨在减少对流感和感冒病毒的暴露","url":"https://stock-news.laohu8.com/highlight/detail?id=1109995262","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109995262?lang=zh_cn&edition=full","pubTime":"2025-12-19 21:20","pubTimestamp":1766150456,"startTime":"0","endTime":"0","summary":"Polyrizon 向 FDA 提交 PL-16 病毒阻断剂的前期指定请求，旨在减少对流感和感冒病毒的暴露。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122590563","title":"Polyrizon宣布良好的渗透动力学，支持其鼻用纳洛酮水凝胶项目的推进","url":"https://stock-news.laohu8.com/highlight/detail?id=1122590563","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122590563?lang=zh_cn&edition=full","pubTime":"2025-12-11 21:15","pubTimestamp":1765458914,"startTime":"0","endTime":"0","summary":"Polyrizon宣布良好的渗透动力学，支持其鼻用纳洛酮水凝胶项目的推进","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118176425","title":"Polyrizon发布与市场上市的鼻用纳洛酮产品相比的积极粘附性结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1118176425","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118176425?lang=zh_cn&edition=full","pubTime":"2025-12-03 22:29","pubTimestamp":1764772150,"startTime":"0","endTime":"0","summary":"Polyrizon发布与市场上市的鼻用纳洛酮产品相比的积极粘附性结果","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108302800","title":"Polyrizon宣布按1至6的比例进行普通股反向拆分 - SEC文件","url":"https://stock-news.laohu8.com/highlight/detail?id=1108302800","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108302800?lang=zh_cn&edition=full","pubTime":"2025-11-25 21:05","pubTimestamp":1764075912,"startTime":"0","endTime":"0","summary":"Polyrizon宣布按1至6的比例进行普通股反向拆分 - SEC文件","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2583063750","title":"Polyrizon Ltd.盘中异动 股价大跌6.41%报0.721美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2583063750","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583063750?lang=zh_cn&edition=full","pubTime":"2025-11-14 22:30","pubTimestamp":1763130625,"startTime":"0","endTime":"0","summary":"北京时间2025年11月14日22时30分，Polyrizon Ltd.股票出现异动，股价快速下挫6.41%。截至发稿，该股报0.721美元/股，成交量2.8445万股，换手率0.47%，振幅2.47%。Polyrizon Ltd.股票所在的生物技术行业中，整体涨幅为0.00%。其相关个股中，Cidara Therapeutics, Inc.、Aspire Biopharma Holdings, Inc.、Invivyd, Inc.涨幅较大，Aspire Biopharma Holdings, Inc.、Clearmind Medicine Inc.、Salarius Pharmaceuticals, Inc.较为活跃，换手率分别为686.43%、33.92%、25.30%，振幅较大的相关个股有Silo Pharma, Inc.、Precigen, Inc.、Fennec Pharmaceuticals Inc.，振幅分别为9.19%、7.25%、7.15%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511142230259504b00d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511142230259504b00d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PLRZ"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.polyrizon-biotech.com","stockEarnings":[{"period":"1week","weight":0.0307},{"period":"1month","weight":0.042},{"period":"3month","weight":0.1717},{"period":"6month","weight":2.9983},{"period":"1year","weight":1.4214},{"period":"ytd","weight":0.7968}],"compareEarnings":[{"period":"1week","weight":0.0088},{"period":"1month","weight":0.0484},{"period":"3month","weight":0.0815},{"period":"6month","weight":0.1314},{"period":"1year","weight":0.2788},{"period":"ytd","weight":0.0934}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Polyrizon Ltd.于2005年1月在以色列注册成立。该公司是一家处于发展阶段的生物技术公司，专门开发以鼻喷雾剂形式交付的创新医疗器械水凝胶，该水凝胶在鼻腔内形成一层薄薄的基于水凝胶的防护屏障，可以防止病毒和过敏原接触鼻上皮组织。该公司的C&C水凝胶技术由天然存在的构建块的混合物组成，以鼻喷雾剂的形式提供，并可用作“生物面具”，在鼻腔内有一层薄薄的防护屏障。该公司正在进一步开发其专有的C&C水凝胶技术的某些方面，例如生物粘附性和在鼻腔沉积部位的延长保留时间，以用于鼻内给药。该公司将其专注于API鼻腔给药的独立平台技术称为T&T。","exchange":"NASDAQ","name":"Polyrizon Ltd.","nameEN":"Polyrizon Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Polyrizon Ltd.(PLRZ)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Polyrizon Ltd.(PLRZ)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Polyrizon Ltd.,PLRZ,Polyrizon Ltd.股票,Polyrizon Ltd.股票老虎,Polyrizon Ltd.股票老虎国际,Polyrizon Ltd.行情,Polyrizon Ltd.股票行情,Polyrizon Ltd.股价,Polyrizon Ltd.股市,Polyrizon Ltd.股票价格,Polyrizon Ltd.股票交易,Polyrizon Ltd.股票购买,Polyrizon Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Polyrizon Ltd.(PLRZ)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Polyrizon Ltd.(PLRZ)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}